The Directorate General of Drug Administration is the main regulator for medical devices and in-vitro diagnostics, acting under the Drugs and Cosmetics Act 2023 and its guidelines. It handles registration, import-related permissions, manufacturing licences and market surveillance. Other bodies may also be involved: radiation-emitting equipment needs licensing from the Bangladesh Atomic Energy Regulatory Authority, some electrical items raise standards questions, and telecommunications equipment may need type approval. We confirm the complete list of authorities for each product before an application is filed, because missing one usually surfaces at the port. Customs officers check these points closely.

It usually helps, because evidence of approval or certification by a recognised overseas regulator supports the safety and performance case and may reduce the depth of local review. It does not replace Bangladesh registration. The dossier must still meet local requirements on format, labelling, the local applicant, free sale or similar certificates and, where relevant, testing. Differences between the approved overseas version and the product being shipped to Bangladesh, such as a different manufacturing site or labelling, can cause queries. We check these points before submission to reduce back-and-forth with the regulator. Translations should also be checked.

In practice, a foreign manufacturer of medical devices usually works through a Bangladeshi importer or local representative who applies for and holds the registration and import permissions. A manufacturer that wants more control can establish a local subsidiary, with approvals now handled by Invest Bangladesh, or appoint an independent regulatory representative separate from its commercial distributor. Each model involves trade-offs on cost, speed and control. The key is to document clearly who owns the registration, how it can be transferred, and what cooperation the holder must give if the commercial relationship ends. We can help compare the options.

This is a common problem for medical devices in Bangladesh, and transition terms are best agreed before signing. If the registration is held by the distributor, termination can leave the manufacturer without a lawful route to supply while a new registration is obtained, and the outgoing distributor may use that leverage in negotiations. A well-drafted agreement deals with this in advance: cooperation obligations on transfer or withdrawal, handover of technical and post-market records, transition periods and stock buy-back. Where the agreement is silent, we advise on negotiation strategy, regulatory options and any claims available on either side.

It depends mainly on intended purpose and the claims you make. Software that diagnoses, predicts, monitors or guides treatment decisions for individual patients is more likely to be regulated as one of the medical devices in its class, while software that only manages appointments, records or general wellness information may fall outside device rules. Bangladesh practice on software is still developing, so marketing claims, user interface wording and clinical evidence should be reviewed together. Separately, data protection, telemedicine and consumer law obligations may apply whatever the device classification turns out to be. Early review avoids rework later.

Public procurement is a major route to market for medical devices and diagnostics in Bangladesh. Tender documents typically require proof of registration, manufacturer authorisation, specific certificates, past supply records, warranties, servicing commitments and sometimes local presence. A product that is registered but lacks the specific documents a tender demands may be rejected on technical grounds. We help suppliers check tender conditions against their regulatory position, prepare compliant bids and, where a bid is unfairly rejected, consider complaint and review mechanisms under the public procurement rules within the short deadlines that apply. Keep the tender notice and rejection letter.

Start by preserving information and assessing the event against your vigilance procedure and the reporting expectations of the DGDA and the manufacturer's other regulators. Decide quickly whether a field safety corrective action or recall is needed, who will notify hospitals and users, and how the distributor and service partners will support the response. Communications should be accurate and consistent across markets. We advise on notification, recall logistics, insurer notice, document preservation and the parallel risk of consumer complaints, contract claims and negligence actions arising from the same event. Record each decision and its reasons.

You will need a manufacturing licence and compliance with Bangladesh requirements at home, plus whatever the destination market requires, which for regulated markets often means a certified quality management system, a technical file, conformity assessment and a local authorised representative or importer. Export contracts should address who bears regulatory cost, product liability, recalls and intellectual property in the technical documentation. We coordinate with counsel in the destination country on foreign rules and handle the Bangladesh side, including export formalities, payment terms and security and foreign exchange repatriation. Check early whether repeat testing is needed in the destination market.